v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Jan. 31, 2019
Jan. 31, 2018
Revenue
Operating costs and expenses:    
Inventor royalties, contingent legal fees, litigation and licensing expenses related to patent assertion 25,353
Amortization of patents 251,250 81,324
Research and development expenses (including non-cash share-based compensation expenses of $1,573,779 and $40,057, respectively) 2,247,272 777,873
General and administrative expenses (including non-cash share-based compensation expenses of $1,176,385 and $226,916, respectively) 2,066,456 990,036
Impairment in carrying amount of patent asset (Note 1) 418,750
Total operating costs and expenses 4,983,728 1,874,586
Loss from operations (4,983,728) (1,874,586)
Interest income 17,119 9,112
Loss before income taxes (4,966,609) (1,865,474)
Provision for income taxes
Net loss (4,966,609) (1,865,474)
Less: Net loss attributable to noncontrolling interest (84,768) (27,402)
Net loss attributable to common shareholders $ (4,881,841) $ (1,838,072)
Net loss per common share attributable to common shareholders:    
Basic and diluted (in Dollars per share) $ (0.25) $ (0.11)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 19,170,591 16,610,770

Source